Matrix Leads $15M Series A1 Funding In Anti-Tumor Drug Firm QnQuality

QnQuality Pharmaceuticals Ltd., a Shanghai-based drug R&D company, announces on Monday that it has raised US$15 million in a series A1 funding round led by venture capital firm Matrix Partners China and healthcare-focused venture capital company BioTrack Capital.

China Money Network

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech


Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!


Already have an account or paid subscription? Log in

Caishen.Co - Primary Data for China Secondary Investment and Stock Markets

LEAVE A REPLY